Comparable stake leader
Janus Henderson Group Ltd.
SEC ownership of Lexeo Therapeutics, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001907108.
Disclosed value leader
Janus Henderson Group Ltd.
Comparable rows
50/50
Latest evidence
30 Jun 2026
- Public ticker
- LXEO on Nasdaq
- Parsed ownership sources
-
13D/G, 13F, and 3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
Janus Henderson Group Ltd.
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
50 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
Janus Henderson Group Ltd.
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
30 Jun 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001907108
- Issuer location
- New York, NY
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Lexeo Therapeutics, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Janus Henderson Group Ltd.
Disclosed value leader
Janus Henderson Group Ltd.
Comparable rows
50/50
Latest evidence
30 Jun 2026
13D/G
13F
3/4/5
Lead comparable stake: 10%
13D/G row: Janus Henderson Group Ltd.
Showing 1-8 of 50 holder rows.
Quick read
Janus Henderson Group Ltd. leads the comparable SEC ownership view at 10%.
50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Janus Henderson Group Ltd.'s linked filing trail.
Comparable ownership
Top 5
Janus Henderson Group Ltd.
10%
BALYASNY ASSET MANAGEMENT L.P.
10%
Affinity Asset Advisors, LLC
8.4%
MONTANOVA CAPITAL, LLC
7.7%
Vestal Point Capital, LP
7.5%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Janus Henderson Group Ltd. |
13D/G
JANUS HENDERSON GROUP PLC
|
10%
|
$65,914,563
7,291,434 shares
|
+$10,720,599 | 28 Nov 2025 |
| BALYASNY ASSET MANAGEMENT L.P. |
13D/G
13F
Company
|
10%
|
$36,083,831
7,844,311 shares
|
+$3,073,568 | 30 Jun 2026 |
| Affinity Asset Advisors, LLC |
13D/G
13F
Company
|
8.4%
|
$30,704,600
6,674,913 shares
|
+$6,703,364 | 30 Jun 2026 |
| MONTANOVA CAPITAL, LLC |
13D/G
13F
SUVRETTA CAPITAL MANAGEMENT, LLC · Company
|
7.7%
|
$32,573,226
5,674,778 shares
|
$0 | 06 Apr 2026 |
| Vestal Point Capital, LP |
13D/G
13F
Company
|
7.5%
|
$27,338,885
4,117,302 shares
|
+$5,903,896 | 30 Sep 2025 |
| CITADEL ADVISORS LLC |
13D/G
13F
Kenneth Griffin · Company
|
7.4%
|
$40,851,767
5,498,219 shares
|
+$1,219,315 | 31 Dec 2025 |
| RA CAPITAL MANAGEMENT, L.P. |
13D/G
13F
Company
|
6.9%
|
$33,200,000
5,000,000 shares
|
$0 | 20 Oct 2025 |
| BlackRock, Inc. |
13D/G
13F
Company
|
6.7%
|
$48,518,087
4,885,814 shares
|
+$26,984,571 | 31 Dec 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to selling over the last 12 months. Net value: -$985,080.
Buys
$0
Insiders: 0
Sells
$985,080
Insiders: 7
Net
-$985,080
Shares: -168,601
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 168,601
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 66,326 | $0 | $299,805 | -$299,805 |
| 3-6 | 0 | 59,644 | $0 | $336,670 | -$336,670 |
| 6-9 | 0 | 13,189 | $0 | $84,218 | -$84,218 |
| 9-12 | 0 | 29,442 | $0 | $264,387 | -$264,387 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-20 of 21 reporting-owner rows connected to Lexeo Therapeutics, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
21
Largest Forms 3/4/5 holder
Longitude Capital Partners IV, LLC
Net 12M change
-$985,081
Latest report
18 Aug 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Longitude Capital Partners IV, LLC | 10%+ Owner | $33,933,468 | Mixed | 07 Nov 2023 | ||
| Omega Fund VI, L.P. | 10%+ Owner | $28,520,755 | Mixed | 07 Nov 2023 | ||
| Invest A/s Lundbeckfond | 10%+ Owner | $24,268,808 | Mixed | 07 Nov 2023 | ||
| Richard Nolan Townsend | Chief Executive Officer, Director | $1,854,085 | -$655,676 | -26% | Filing P/S | 18 Aug 2026 |
| Jose Manuel Otero | Chief Operating Officer | $675,047 | -$78,864 | -10% | Filing P/S | 18 Aug 2026 |
| Eric Adler | Chief Medical Officer | $673,428 | -$35,943 | -5.1% | Filing P/S | 18 Nov 2025 |
| Jenny Robertson | Chief Legal Officer | $633,891 | -$36,619 | -5.5% | Filing P/S | 18 Nov 2025 |
| Tai Sandi See | Chief Development Officer | $606,962 | -$38,345 | -5.9% | Filing P/S | 18 Nov 2025 |
| Louis Edward Tamayo | Chief Financial Officer | $455,903 | -$41,041 | -8.3% | Filing P/S | 18 Aug 2026 |
| Narinder Pal Bhalla | Chief Medical Officer | $363,297 | -$98,593 | -21% | Filing P/S | 29 Jun 2026 |
| Kyle Rasbach | Chief Financial Officer | $335,032 | Mixed | 17 Jan 2025 | ||
| Paul McCormac | Chief Technical Officer | $229,329 | Mixed | 07 Nov 2023 | ||
| Paula H. Cholmondeley | Director | $214,086 | Filing P/S | 25 Jun 2026 | ||
| Bernard Davitian | Director | Mixed | 02 Nov 2023 | |||
| Reinaldo M. Diaz | Director | Mixed | 25 Jun 2026 | |||
| Steven Altschuler | Director | Mixed | 25 Jun 2026 | |||
| Laura Sepp-Lorenzino | Director | Mixed | 28 Apr 2026 | |||
| Brenda Cooperstone | Director | Mixed | 25 Jun 2026 | |||
| Timothy van Hauwermeiren | Director | Mixed | 25 Jun 2026 | |||
| Tolga Tanguler | Director | Mixed | 25 Jun 2026 |
Recent insider transactions for Lexeo Therapeutics, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Louis Edward Tamayo | LXEO | Common Stock | Sale | -4.24% | $20,203 | $4.91 | -4,117 | 92,907 | 18 Aug 2026 | Direct |
| Richard Nolan Townsend | LXEO | Common Stock | Sale | -0.89% | $16,562 | $4.95 | -3,345 | 374,472 | 18 Aug 2026 | Direct |
| Jose Manuel Otero | LXEO | Common Stock | Sale | -0.95% | $6,464 | $4.96 | -1,304 | 136,178 | 18 Aug 2026 | Direct |
| Louis Edward Tamayo | LXEO | Common Stock | Sale | -4.56% | $20,838 | $4.49 | -4,641 | 97,024 | 01 Jul 2026 | Direct |
| Jose Manuel Otero | LXEO | Common Stock | Sale | -3.28% | $20,904 | $4.48 | -4,666 | 137,482 | 01 Jul 2026 | Direct |
| Narinder Pal Bhalla | LXEO | Common Stock | Sale | -21.4% | $98,593 | $4.42 | -22,306 | 82,194 | 01 Jul 2026 | Direct |
| Richard Nolan Townsend | LXEO | Common Stock | Sale | -6.43% | $116,243 | $4.48 | -25,947 | 377,817 | 01 Jul 2026 | Direct |
| Louis Edward Tamayo | LXEO | Common Stock | Award | 13.4% | 12,000 | 101,665 | 29 Jun 2026 | Direct | ||
| Jose Manuel Otero | LXEO | Common Stock | Award | 9.27% | 12,060 | 142,148 | 29 Jun 2026 | Direct | ||
| Narinder Pal Bhalla | LXEO | Common Stock | Award | 111.1% | 55,000 | 104,500 | 29 Jun 2026 | Direct | ||
| Richard Nolan Townsend | LXEO | Common Stock | Award | 19.9% | 67,000 | 403,764 | 29 Jun 2026 | Direct | ||
| Steven Altschuler | LXEO | Stock Option (right to buy) | Award | 35,000 | 35,000 | 25 Jun 2026 | Direct | |||
| Mette Kirstine Agger | LXEO | Stock Option (right to buy) | Award | 35,000 | 35,000 | 25 Jun 2026 | Direct | |||
| Brenda Cooperstone | LXEO | Stock Option (right to buy) | Award | 35,000 | 35,000 | 25 Jun 2026 | Direct | |||
| Reinaldo M. Diaz | LXEO | Stock Option (right to buy) | Award | 35,000 | 35,000 | 25 Jun 2026 | Direct | |||
| Tolga Tanguler | LXEO | Stock Option (right to buy) | Award | 35,000 | 35,000 | 25 Jun 2026 | Direct | |||
| Timothy van Hauwermeiren | LXEO | Stock Option (right to buy) | Award | 35,000 | 35,000 | 25 Jun 2026 | Direct | |||
| Paula H. Cholmondeley | LXEO | Stock Option (right to buy) | Award | 35,000 | 35,000 | 25 Jun 2026 | Direct | |||
| Jose Manuel Otero | LXEO | Common Stock | Sale | -0.99% | $6,606 | $5.07 | -1,302 | 130,088 | 18 May 2026 | Direct |
| Richard Nolan Townsend | LXEO | Common Stock | Sale | -0.98% | $16,927 | $5.06 | -3,342 | 336,764 | 18 May 2026 | Direct |
| Laura Sepp-Lorenzino | LXEO | Stock Option (right to buy) | Award | 50,000 | 50,000 | 28 Apr 2026 | Direct | |||
| Richard Nolan Townsend | LXEO | Common Stock | Sale | -13.9% | $313,137 | $5.69 | -55,000 | 340,106 | 06 Apr 2026 | Direct |
| Richard Nolan Townsend | LXEO | Common Stock | Award | 0.67% | 2,623 | 395,106 | 13 Mar 2026 | Direct | ||
| Jose Manuel Otero | LXEO | Common Stock | Award | 4.73% | 5,930 | 131,390 | 13 Mar 2026 | Direct | ||
| Jose Manuel Otero | LXEO | Common Stock | Sale | -2.35% | $19,294 | $6.40 | -3,016 | 125,460 | 18 Feb 2026 | Direct |
| Richard Nolan Townsend | LXEO | Common Stock | Sale | -2.53% | $64,924 | $6.38 | -10,173 | 392,483 | 18 Feb 2026 | Direct |
| Narinder Pal Bhalla | LXEO | Common Stock | Award | 49,500 | 49,500 | 13 Feb 2026 | Direct | |||
| Narinder Pal Bhalla | LXEO | Stock Option (right to buy) | Award | 297,000 | 297,000 | 13 Feb 2026 | Direct | |||
| Richard Nolan Townsend | LXEO | Common Stock | Award | 67.1% | 161,665 | 402,656 | 04 Feb 2026 | Direct | ||
| Richard Nolan Townsend | LXEO | Stock Option (right to buy) | Award | 646,665 | 646,665 | 04 Feb 2026 | Direct | |||
| Jose Manuel Otero | LXEO | Common Stock | Award | 102.4% | 65,000 | 128,476 | 04 Feb 2026 | Direct | ||
| Jose Manuel Otero | LXEO | Stock Option (right to buy) | Award | 260,000 | 260,000 | 04 Feb 2026 | Direct | |||
| Louis Edward Tamayo | LXEO | Common Stock | Award | 99.3% | 44,665 | 89,665 | 04 Feb 2026 | Direct | ||
| Louis Edward Tamayo | LXEO | Stock Option (right to buy) | Award | 226,665 | 226,665 | 04 Feb 2026 | Direct | |||
| Jose Manuel Otero | LXEO | Common Stock | Sale | -1.12% | $6,684 | $9.27 | -721 | 63,476 | 18 Nov 2025 | Direct |
| Richard Nolan Townsend | LXEO | Common Stock | Sale | -0.47% | $10,447 | $9.27 | -1,127 | 240,991 | 18 Nov 2025 | Direct |
| Eric Adler | LXEO | Common Stock | Sale | -0.84% | $5,701 | $9.27 | -615 | 72,646 | 18 Nov 2025 | Direct |
| Tai Sandi See | LXEO | Common Stock | Sale | -0.59% | $3,578 | $9.27 | -386 | 65,476 | 18 Nov 2025 | Direct |
| Jenny Robertson | LXEO | Common Stock | Sale | -0.8% | $5,089 | $9.27 | -549 | 68,381 | 18 Nov 2025 | Direct |
| Tai Sandi See | LXEO | Common Stock | Sale | -5.57% | $34,767 | $8.94 | -3,888 | 65,862 | 17 Oct 2025 | Direct |
| Jenny Robertson | LXEO | Common Stock | Sale | -4.87% | $31,530 | $8.94 | -3,526 | 68,930 | 17 Oct 2025 | Direct |
| Jose Manuel Otero | LXEO | Common Stock | Sale | -3.19% | $18,913 | $8.94 | -2,115 | 64,197 | 17 Oct 2025 | Direct |
| Eric Adler | LXEO | Common Stock | Sale | -4.41% | $30,242 | $8.94 | -3,382 | 73,261 | 17 Oct 2025 | Direct |
| Richard Nolan Townsend | LXEO | Common Stock | Sale | -5.15% | $117,436 | $8.94 | -13,133 | 242,118 | 17 Oct 2025 | Direct |
| Tai Sandi See | LXEO | Common Stock | Award | 18.5% | 10,890 | 69,750 | 15 Oct 2025 | Direct | ||
| Jenny Robertson | LXEO | Common Stock | Award | 15.8% | 9,900 | 72,456 | 15 Oct 2025 | Direct | ||
| Jose Manuel Otero | LXEO | Common Stock | Award | 9.84% | 5,940 | 66,312 | 15 Oct 2025 | Direct | ||
| Eric Adler | LXEO | Common Stock | Award | 14.3% | 9,570 | 76,643 | 15 Oct 2025 | Direct | ||
| Richard Nolan Townsend | LXEO | Common Stock | Award | 14.8% | 33,000 | 255,251 | 15 Oct 2025 | Direct |
* marks a reported price that did not pass the local price check.